B. Maasoumy

发表

HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.

J. Pawlotsky, J. Rockstroh, C. Sarrazin, 2017, Journal of Virological Methods.

Significant compartment‐specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection

M. Manns, H. Wedemeyer, D. Todt, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen

J. Pawlotsky, C. Sarrazin, H. Wedemeyer, 2016, Antiviral therapy.

Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response

J. Pawlotsky, C. Sarrazin, H. Wedemeyer, 2016, Scientific Reports.

Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis

Maciej K. Janik, M. Manns, S. Dübel, 2021, Hepatology.

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

A. Ganser, J. Krauss, F. Donnerstag, 2021, Blood.

Breakthroughs in hepatitis C research: from discovery to cure

M. Manns, B. Maasoumy, 2022, Nature Reviews Gastroenterology & Hepatology.

Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatitis C‐Registry (DHC‐R)

H. Wedemeyer, A. Schäfer, B. Maasoumy, 2021, Journal of viral hepatitis.

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy

M. Manns, S. Zeuzem, C. Sarrazin, 2019, PloS one.

Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms

E. Paxinos, C. Sarrazin, H. Wedemeyer, 2017, Journal of Clinical Microbiology.

Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis

M. Manns, C. Sarrazin, H. Wedemeyer, 2014, PloS one.

The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C

H. Wedemeyer, B. Maasoumy, M. Cornberg, 2013, Alimentary pharmacology & therapeutics.

Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy

M. Manns, D. Back, F. Marra, 2020, Open forum infectious diseases.

Editorial: retreatment of DAA‐failures—no problem at all?

B. Maasoumy, C. Höner Zu Siederdissen, C. Höner zu Siederdissen, 2018, Alimentary pharmacology & therapeutics.

Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.

M. Manns, J. Pawlotsky, S. Zeuzem, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Eligibility and safety of the first interferon‐free therapy against hepatitis C in a real‐world setting

M. Manns, H. Wedemeyer, B. Maasoumy, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study.

H. Wedemeyer, H. Kessler, P. Halfon, 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.

M. Manns, J. Pawlotsky, S. Zeuzem, 2016, Journal of hepatology.

Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA

M. Manns, H. Wedemeyer, K. Böker, 2014, PLoS ONE.

Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease

M. Manns, H. Wedemeyer, B. Maasoumy, 2014, European journal of gastroenterology & hepatology.

Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients.

H. Wedemeyer, A. Potthoff, B. Maasoumy, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Extrahepatic Manifestations of Hepatitis C Virus Infection

M. Manns, B. Maasoumy, M. Cornberg, 2013 .

Impact of the COVID-19 pandemic on patients with liver cirrhosis—the experience of a tertiary center in Germany

H. Wedemeyer, B. Maasoumy, M. Cornberg, 2021, Zeitschrift für Gastroenterologie.

Breakthroughs in hepatitis C research: from discovery to cure

M. Manns, B. Maasoumy, 2022, Nature Reviews Gastroenterology & Hepatology.

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice

B. Maasoumy, Christopher Dietz, 2022, Viruses.

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

A. Ganser, J. Krauss, F. Donnerstag, 2021, Blood.

Systemic arterial blood pressure determines the therapeutic window of non‐selective beta blockers in decompensated cirrhosis

M. Manns, B. Maasoumy, M. Cornberg, 2019, Alimentary pharmacology & therapeutics.

FIB-4 and APRI as Predictive Factors for Short- and Long-Term Survival in Patients with Transjugular Intrahepatic Portosystemic Stent Shunts

A. Wetter, J. Theysohn, B. Maasoumy, 2022, Biomedicines.

Home‐based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites

H. Wedemeyer, B. Maasoumy, E. Jaeckel, 2022, Alimentary pharmacology & therapeutics.

Prevalence of hepatitis D virus co-infection in Austria - Finding the needle in the haystack.

B. Maasoumy, M. Sonneveld, 2021, United European gastroenterology journal.

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection

H. Wedemeyer, B. Maasoumy, B. Bremer, 2021, Gut.

Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis

M. Buti, T. Berg, F. Zoulim, 2021, Alimentary pharmacology & therapeutics.

Editorial: pressure to close the therapeutic window of non‐selective beta blockers? Authors’ reply

B. Maasoumy, T. Tergast, 2019, Alimentary pharmacology & therapeutics.

Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites

M. Manns, B. Maasoumy, M. Cornberg, 2020, United European gastroenterology journal.

Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data.

M. Buti, M. Honda, Hwai I. Yang, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany

H. Wedemeyer, B. Maasoumy, R. Vonberg, 2021, BMC Gastroenterology.

Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B.

M. Manns, E. Herrmann, H. Wedemeyer, 2016, The Journal of infectious diseases.

Application of CT contrast medium is not associated with an increased risk for acute kidney injury in patients with decompensated cirrhosis

Julius J Schmidt, H. Wedemeyer, J. Kahlhöfer, 2022, Alimentary pharmacology & therapeutics.

Metamizole-Associated Risks in Decompensated Hepatic Cirrhosis.

H. Wedemeyer, J. Kahlhöfer, B. Maasoumy, 2022, Deutsches Arzteblatt international.

Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications

M. Manns, B. Maasoumy, L. Sandmann, 2019, Visceral Medicine.

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

M. Manns, C. Sarrazin, S. Mauss, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome

C. Labenz, M. Kirstein, T. Austgen, 2022, United European gastroenterology journal.

[Treatment strategies for acute-on-chronic liver failure].

M. Manns, B. Maasoumy, Abdul-Rahman Kabbani, 2019, Medizinische Klinik, Intensivmedizin und Notfallmedizin.

New viral biomarkers for Hepatitis B: Are we able to change practice?

B. Maasoumy, M. Cornberg, C. Höner zu Siederdissen, 2018, Journal of viral hepatitis.

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D.

H. Wedemeyer, D. Glebe, B. Maasoumy, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Low anti‐HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen‐negative patients

H. Wedemeyer, B. Maasoumy, B. Bremer, 2022, Liver international : official journal of the International Association for the Study of the Liver.

What is new on HBsAg and other diagnostic markers in HBV infection?

B. Maasoumy, M. Cornberg, C. Höner zu Siederdissen, 2017, Best practice & research. Clinical gastroenterology.

Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting

M. Manns, H. Wedemeyer, B. Maasoumy, 2013, PloS one.

Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin als Reserveregime nach Sofosbuvir + Velpatasvir + Voxilaprevir Re-Therapieversagen

B. Maasoumy, M. Cornberg, L. Sandmann, 2021, Zeitschrift für Gastroenterologie.

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta

M. Manns, C. Yurdaydın, H. Wedemeyer, 2021, Hepatology communications.

PREDICTION OF SUSTAINED RESPONSE AFTER NUCLEO(S)TIDE ANALOGUE CESSATION USING HBSAG AND HBCRAG LEVELS - A MULTICENTER STUDY (CREATE).

M. Buti, T. Berg, F. Zoulim, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB

H. Wedemeyer, S. Binder, C. Falk, 2020, Hepatology communications.

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.

M. Buti, T. Berg, F. Zoulim, 2022, Journal of hepatology.

How to interpret borderline HCV antibody test results: a comparative study investigating four different anti-HCV assays.

M. Manns, H. Wedemeyer, B. Maasoumy, 2014, Viral immunology.

Diagnostics in hepatitis C: The end of response-guided therapy?

B. Maasoumy, J. Vermehren, 2016, Journal of hepatology.

Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort.

M. Manns, H. Wedemeyer, D. Back, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis

T. Berg, C. Sarrazin, H. Wedemeyer, 2014, Alimentary pharmacology & therapeutics.

Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir

H. Wedemeyer, P. Halfon, B. Maasoumy, 2014, Alimentary pharmacology & therapeutics.

Induction of a mature hepatocyte phenotype in adult liver derived progenitor cells by ectopic expression of transcription factors.

M. Manns, A. Schambach, I. Popescu, 2011, Stem cell research.

Reverse Inflammaging: Long-term effects of HCV cure on biological age

Y. Mekonnen, H. Wedemeyer, B. Maasoumy, 2022, medRxiv.

Inferior cure rate in pilot study of 4‐week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C

J. Bukh, L. Madsen, B. Maasoumy, 2021, Liver International.

Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience

H. Wedemeyer, B. Maasoumy, M. Cornberg, 2021, Open forum infectious diseases.

Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA.

H. Wedemeyer, B. Maasoumy, B. Bremer, 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Natural history of acute and chronic hepatitis C.

H. Wedemeyer, B. Maasoumy, 2012, Best practice & research. Clinical gastroenterology.

Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study

M. Manns, H. Stellbrink, C. Cordes, 2022, JHEP reports : innovation in hepatology.

MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis

M. Manns, C. Falk, B. Maasoumy, 2020, Hepatology.

The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients

M. Manns, H. Wedemeyer, A. Potthoff, 2019, Scandinavian journal of gastroenterology.

Optimal treatment with boceprevir for chronic HCV infection

M. Manns, B. Maasoumy, 2013, Liver international : official journal of the International Association for the Study of the Liver.

Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study

M. Manns, E. Paxinos, C. Sarrazin, 2017, Therapeutic advances in gastroenterology.

HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load Determination

H. Wedemeyer, A. Geretti, R. Delgado, 2020, Hepatology communications.

Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS

M. Manns, H. Wedemeyer, B. Maasoumy, 2021, Hepatology communications.

Prospective assessment of subclinical cardiovascular damage and associated factors in liver transplant recipients

A. Melk, F. Vondran, B. Maasoumy, 2020, Transplant international : official journal of the European Society for Organ Transplantation.

HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.

J. Pawlotsky, M. Kowgier, C. Sarrazin, 2018, The lancet. Gastroenterology & hepatology.

Kinetics and predictive value of HBcrAg, HBV RNA and anti‐HBc during bulevirtide treatment of chronic HDV‐infected patients

H. Wedemeyer, B. Maasoumy, B. Bremer, 2023, Journal of viral hepatitis.

IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?

H. Wedemeyer, B. Maasoumy, M. Cornberg, 2021, Journal of hepatology.

Hepatitis E virus is highly resistant to alcohol-based disinfectants.

H. Wedemeyer, R. Ulrich, D. Todt, 2022, Journal of hepatology.

Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis

M. Manns, B. Maasoumy, M. Cornberg, 2019, PloS one.

Correction to: Transjugular intrahepatic portosystemic shunt placement: portal vein puncture guided by 3D/2D image registration of contrast-enhanced multi-detector computed tomography and fluoroscopy

F. Wacker, M. Kirstein, B. Maasoumy, 2020, Abdominal Radiology.

Dose‐dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis

M. Manns, B. Maasoumy, M. Cornberg, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Letter to the Editor: Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels Author reply.

C.-H. Chen, B. Maasoumy, M. Sonneveld, 2022, Journal of hepatology.

Letter: a 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis

M. Manns, H. Wedemeyer, B. Maasoumy, 2020, Alimentary pharmacology & therapeutics.

Percutaneous Transsplenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness

F. Wacker, B. Maasoumy, E. Jaeckel, 2022, CardioVascular and Interventional Radiology.

Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites

M. Manns, B. Maasoumy, M. Cornberg, 2020, PloS one.

Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study.

S. Ciesek, A. Heim, E. Stelzl, 2021, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

A transient early HBV‐DNA increase during PEG‐IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV‐RNA and HBsAg reduction

M. Manns, C. Yurdaydın, S. Zeuzem, 2020, Journal of viral hepatitis.

Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience

F. Tacke, T. Seufferlein, A. Lohse, 2022, Journal of Hepatology.

Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity

J. Sheldon, T. von Hahn, B. Maasoumy, 2021, Cells.

Nosocomial infections in female compared with male patients with decompensated liver cirrhosis

M. Manns, H. Wedemeyer, B. Maasoumy, 2022, Scientific Reports.

Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites

M. Manns, B. Maasoumy, M. Cornberg, 2018, Clinical and Translational Gastroenterology.

Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study)

M. Manns, H. Stellbrink, C. Cordes, 2022, Journal of Hepatology.

Utility of viral kinetics in HCV therapy – It is not over until it is over?

M. Manns, B. Maasoumy, Michael P Manns, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Renal function in HCV therapy: Just another thing to ignore?

B. Maasoumy, V. Ohlendorf, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis.

M. Manns, Julius J Schmidt, H. Wedemeyer, 2021, Journal of hepatology.

Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?

B. Maasoumy, M. Cornberg, T. Tergast, 2021, Journal of hepatology.

3P and 5P model of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta.

H. Wedemeyer, B. Maasoumy, K. Deterding, 2023, Journal of Hepatology.

SUPPLEMENT

A. Ganser, J. Krauss, H. Wedemeyer, 1966 .

Antiviral Therapy of Chronic Hepatitis D Virus Infection – Addendum to the S3 Guideline “Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection” of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS)

E. Schott, B. Maasoumy, J. Vermehren, 2023, Zeitschrift für Gastroenterologie.

Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.

B. Hofer, B. Maasoumy, M. Mandorfer, 2024, Journal of hepatology.

Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA

B. Maasoumy, K. Deterding, K. Port, 2023, Journal of viral hepatitis.

Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.

F. Tacke, T. Berg, U. Merle, 2023, JHEP reports : innovation in hepatology.

Off-label Bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease

P. Lampertico, P. Buggisch, J. Wiegand, 2023, Journal of Hepatology.

Hepatitis C treatment before and after kidney transplantation

B. Maasoumy, J. Friebus-Kardash, J. Eichholz, 2024, Die Nephrologie.